Browse by Audience
Skip to content
Papers of the Week
Efficacy and safety of nemolizumab in paediatric patients aged 6-12 years with atopic dermatitis with moderate-to-severe pruritus: Results from a phase III, randomised, double-blind, placebo-controlled, multicentre study.
Authors
Igarashi A, Katsunuma T, Matsumura T, Komazaki HAbstract
Atopic dermatitis (AD) is a chronic, inflammatory skin condition affecting up to one-quarter of children. Uncontrolled pruritus associated with childhood AD, and the accompanying scratching, negatively impacts quality of life (QoL), sleep, and development. The humanised monoclonal antibody nemolizumab, used concomitantly with topical agents, was shown to reduce pruritus and improve QoL in patients with AD aged ≥13 years. However, data relating to its efficacy and safety in younger children (aged <13 years) have been lacking.